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Reticulocyte hemoglobin equivalent (RET-He) represents hemoglobin content in reticulocytes. 
Reticulocyte hemoglobin equivalent test can assess the iron status of chronic kidney disease (CKD). 
Iron deficiency happens in 40% CKD and can lead to anemia manifestation. The RET-He level gives 
a real-time assessment of iron availability for hemoglobin production, and the level will be getting 
lower when iron storage for erythropoiesis decreasing. Reticulocyte hemoglobin equivalent is more 
stable than ferritin and transferrin saturation in assessing iron status. This study aimed to determine 
RET-He level in patients with CKD stage IV and V. This study was a cross-sectional descriptive study. 
Subjects were 96 CKD stage IV and V patients that met inclusion and exclusion criteria. Subjects 
conducted blood tests at Central Laboratory Installation Dr. M. Djamil Central Public Hospital Padang 
from July to September 2020. Examination of RET-He level was analyzed by Sysmex XN-1000 
flowcytometry fluorescence method. Data was presented in the frequency distribution table. The RET-
He level below cut-off (<29,2 pg) indicated the need for iron supplementation therapy for CKD stage 
IV and V patients. Samples with RET-He level below cut-off were 48 (50%), and 48 (50%) were above 
the cut-off. 
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INTRODUCTION 
Chronic kidney disease (CKD) is 
characterized by progressive and permanent loss 
of kidney functions. A decrease in glomerulus 
filtration rate (GFR) ≤60 ml/min/1.73 m2 for 
three months or more in adults indicates loss of 
normal kidney functions for half or more. 
Chronic kidney disease is divided into five stages 
based on GFR, with stage I-III being a mild-
moderate stage while stage IV-V are severe 
stages and require hemodialysis.1,3 
Chronic kidney disease is a global public 
health problem with increasing prevalence and 
incidence of kidney failure, poor prognosis, and 
high cost. The prevalence of CKD increases with 
the increasing number of older people with an 
incidence of diabetes mellitus and hypertension.4 
Prevalence of CKD stage I-V globally was 
13.4%.5 Prevalence in males was higher than 
female by the ratio of two to three.6  
Anemia is a common complication in 
CKD.7,10 Anemia prevalence in CKD is inversely 
correlated with renal function, and most CKD 
stage V have anemia.11 Prevalence CKD stage IV 
and V in children exceeded 87%.10 Anemia in 
CKD is associated with decreased quality of life 
and increased risk of cardiovascular disease, 
cognitive impairment, and even death.9 The main 
cause of anemia in CKD is a relative deficiency 
in erythropoietin production. Other possible 
contributing factors include iron deficiency, 
blood loss, inflammation, hemolysis, and 
nutritional deficiencies.12,13 Optimizing iron 
status is a prerequisite for effective treatment of 
anemia.10  
Iron deficiency occurs in 40% of CKD 
patients and 40-77% of CKD patients 
undergoing hemodialysis (CKD-HD).9 Patients 
with CKD are prone to both absolute iron 
deficiency and so-called functional iron 
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deficiency. Absolute iron deficiency occurs due 
to combination of inadequate iron intake, 
impaired iron absorption in the duodenum, and 
excessive iron loss through intracorporeal 
hemodialysis circuits or gastrointestinal 
bleeding. Meanwhile, functional iron deficiency 
is caused by extracellular iron homeostasis.10,11 
Iron deficiency reduces erythropoietin (EPO) 
therapy response, and therefore, CKD-HD 
patients who have iron-deficiency anemia should 
be given iron supplements simultaneously with 
EPO therapy.9  
Assessment of iron status in adult and 
pediatric CKD patients generally uses a 
combination of serum transferrin and ferritin 
saturation. These tests have limitations on 
biological and analytical variabilities and 
parameter instability during inflammation and 
malnutrition. Alternative tests have been widely 
studied in recent years to replace these two 
parameters, one of which is by assessing the level 
of reticulocyte hemoglobin content (CHr) or 
reticulocyte hemoglobin equivalent (RET-He).10 
 About 2 million out of 50 million CKD 
patients worldwide require hemodialysis as renal 
replacement therapy.2,14 Hemodialysis begins at 
stage CKD stage V or if there are some other 
indications. 8,15 Parameter of CHr or RET-He is 
more stable in assessing iron status of CKD 
patients who are undergoing hemodialysis.7 
National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative (NKF-
KDOQI) in 2006 and the Renal Association in 
2017 had recommended CHr and RET-He to 
assess the iron status of CKD patients.7,16 The 
study of 106 CKD-HD patients conducted by 
Wirawan et al. showed a very strong positive 
correlation and good concordance between 
RET-He and CHr. This result showed that 
clinicians could assess iron supplementation 
targets if patients were examined in different 
laboratories using different hematology 
analyzers. The cut-off value of RET-He as the 
target of iron supplementation in CKD-HD 
patients in the Wirawan's study was 29.2 pg, 
with CHr as the gold standard.9  
Iron availability for erythropoiesis can be 
calculated by measuring iron contained in 
reticulocytes using CHr or RET-He. 
Measurement of CHr can be performed using  
ADVIA analyzer while RET-He using a Sysmex 
analyzer.9 The biological and analytical 
variabilities of CHr and RET-He are better than 
conventional iron status tests.10,17 
Reticulocyte hemoglobin equivalent  (RET-
He) level represents the hemoglobin content in 
reticulocytes, providing real-time information 
on iron availability for erythropoiesis and 
assessing the quality of newly produced cells.18 
Reticulocytes have greater volume, higher 
hemoglobin content, and lower hemoglobin 
concentration than mature red blood cells 
(RBC). Reticulocytes can only synthesize 
hemoglobin while in the bone marrow. Thus, 
once they enter the peripheral blood, they have 
the maximum hemoglobin content they can 
have.19 Therefore,  the changes of iron status can 
be detected much earlier than through the 
hemoglobin content of mature RBC.18 
The RET-He test has various advantages 
over ferritin and transferrin saturation. This test 
can be performed simultaneously with routine 
hematologic examination and not affected by 
acute phase conditions such as inflammation, 
pregnancy, or other serious comorbidities. The 
RET-He test is used to monitor intravenous EPO 
and/or iron therapy. Increased level of RET-He 
indicates the success of therapy.18  
 
MATERIAL AND METHODS 
A cross-sectional descriptive study was 
conducted at the Central Laboratory Installation 
of Dr. M. Djamil Central Public Hospital Padang 
from July 2020 to September 2020.  
The study population was CKD stage IV 
and V patients who examined routine 
hematological parameters. The samples were 
study populations that fulfilled the inclusion and 
exclusion criteria. Inclusion criteria were CKD 
stage IV and V patients. Exclusion criteria were 
CKD stage IV and V patients who: 1) received 
blood transfusions (whole blood or packed red 
cell), 2) consumed iron supplementation therapy, 
3) under EPO therapy within two days before the 
examination. 
Phlebotomy was performed aseptically in 
the vein of the cubital fossa region by trained 
phlebotomists. Volume 3 ml of venous blood 
was inserted into the K3EDTA anticoagulant 
tube. The sample was homogenized immediately 
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by slowly turning the tube eight times and 
avoiding foam formation. Measurement of RET-
He was performed simultaneously with routine 
hematology examination. Level of RET-He was 
measured by fluorescence flowcytometry 
method in Sysmex XN-1000 hematology 
analyzer.  
Data were analyzed descriptively to figure 
out RET-He level in patients with CKD stage IV 
and V. Data was presented in the frequency 
distribution table. In this study, the cut-off value 
of RET-He was using reference by Wirawan et 
al., which was 29.2 pg. The RET-He level below 
cut-off (<29.2 pg) indicated the need for iron 





Study subjects were 96 patients with CKD 
stages IV and V with clinical characteristics 
shown in table 1. 
 
Tabel 1. Subjects' Characteristics 




Age (year)  55 (18-80) 53.8 
(13.2) 
≦ 30 6 (6.3 %)   
31-50 26 (27%)   
51-70 59 (61.5%)   
≧71 5 (5.2%)   
Gender    
Male 50 (52%)   
Female 46 (48%)   
CKD Stage    
Stage IV 3 (3%)   
Stage V 93 (97%)   
 
Study subjects consisted of 52% male and 
46% female. The mean age was 53.8 (13.2) 
years, with a median of 18-80 years. There were 




Hemoglobin and RET-He in CKD Stage IV & 
V Patients 
All subjects (100%) had anemia. Study 
subjects with RET-He ≧29.2 pg were 48 patients 
(50%), and RET-He <29.2 pg was 48 patients 
(50%). The mean of RET-He level in this study 
was 28.8 (4.1), with a median of 29.1 (16-38.9) 
pg. Hemoglobin and RET-He levels in patients 
with CKD stage IV and V can be seen in table 2. 
 
Tabel 2. Hemoglobin and RET-He in CKD 
Stage IV and V Patients 










Male  :  















48 (50%)   
RET-He  
< 29.2 
48 (50%)   
 
DISCUSSION 
Anemia was found in all study subjects. 
Anemia in CKD has multifactorial etiologies. 
The main cause of anemia in CKD is 
erythropoietin production impairment due to 
renal failure.20 Effective erythropoiesis depends 
on adequate availability of both erythropoietin 
and iron. Iron deficiency is common in CKD. 
The reasons for iron deficiency include occult 
blood loss, infection, systemic inflammatory 
conditions, surgical procedures, venipuncture, 
impaired absorption secondary to elevated 
hepcidin concentrations, and in dialysis, 
retention of blood by the dialysis apparatus. It is 
estimated that hemodialysis patients may lose 
≥2,000 mg of iron per year due to these factors.13  
The RET-He level <29.2 pg in this study was 
found in 48 people (50%). Wirawan et al.'s study got 
RET-He cut-off of 29.2 pg as the target for iron 
supplementation in CKD-HD patients.9 The RET-He 
level below this cut-off (<29.2 pg) indicated the need 
for iron supplementation in patients with CKD stages 
IV and V. The RET-He level can measure iron status 
so that anemia severity in CKD caused by iron 
deficiency can be avoided. 
This study had several limitations. First, the 
number of CKD stage IV patients was very 
small, so it could not represent the RET-He level 
of CKD stage IV patients as a whole. We 
intended to examine the RET-He level of all 
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stages of CKD. Still, CKD patients in RSUP Dr. 
M. Djamil mostly were referral patients from 
other health facilities, in which majority of the 




Low RET-He levels in patients with CKD 
stage IV and V were found to be 50%. The iron 
status examination is needed at all stages of 
CKD. Measurement of RET-He level is an 
alternative test for assessing the iron status, and 
it can be performed simultaneously with routine 
hematology examination, making it more 
practical and cost-effective than the conventional 
iron status tests. 
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